Author:
Freedman Orit,Amir Eitan,Dranitsaris George,Napolskikh Julie,Kumar Ritu,Fralick Michael,Chia Stephen,Petrella Teresa,Dent Susan,Tonkin Katia,Ahmad Imran,Rayson Daniel,Clemons Mark
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Pietras RJ (2006) Biologic basis of sequential and combination therapies for hormone-resistant breast cancer. Oncologist 11:704–717
2. Bundred N (2005) Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer. Cancer Invest 23(2):173–181
3. DeFriend DJ, Howell A, Nicholson RI (1994) et al.: Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54:408–414
4. Robertson JFR, Nicholson RI, Bundred NJ (2001) Comparison of the short-term biological effects of 7alpha-[9-(4, 4, 5, 5, 5-pentafluoropentylsulfinyl)-nonyl]estra-1, 3, 5,(10)-triene-3, 17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 61:6739–6746
5. Wakeling AE (2000) Similarities and distinctions in the mode of action of different classes of antiestrogens. End Rel Cancer 7:17–28
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献